Cibiyar Brand ta sanar da nasarar haɗin gwiwa tare da Global Blood Therapeutics (GBT) a cikin sanya sunan maganin da aka yarda da su na EMA, OXBRYTA, wanda aka nuna don maganin anemia na hemolytic saboda cutar sikila (SCD) a cikin manya da yara masu shekaru 12 da haihuwa kamar yadda monotherapy ko a hade tare da hydroxycarbamide (hydroxyurea). Wannan ya biyo bayan amincewar FDA da Lafiyar Kanada na maganin a cikin 2019.
Shugaban Cibiyar Brand da Shugaba James L. Dettore ya ce "Dukkan Cibiyar Brand da Cibiyar Kare Magunguna ta Duniya suna taya Global Blood Therapeutics murna kan amincewar FDA na OXBRYTA," in ji Shugaban Cibiyar Brand, James L. Dettore. "Wannan maganin da ke canza canjin yana da yuwuwar yin babban canji ga waɗanda ke cikin Turai waɗanda ke fama da wannan cuta mai rauni."
OXBRYTA shine magani na farko da aka amince dashi a Turai wanda ke hana sickle haemoglobin (HbS) polymerization kai tsaye, tushen kwayoyin cuta na rashin lafiya da lalata jajayen ƙwayoyin jini a cikin SCD. OXBRYTA yana aiki ta hanyar haɓaka alaƙar haemoglobin don iskar oxygen. Tun da sikila hemoglobin mai iskar oxygen ba ya yin polymerize, OXBRYTA yana hana sickle haemoglobin polymerization da sakamakon rashin lafiya da lalata ƙwayoyin jajayen jini.
"Mun yi imanin sunan alamar OXBRYTA ya dace da samfurin," in ji Dettore. "Bugu da ƙari ga ƙarami da ke da alaƙa da 'oxygen', yana nuni ga tsarin aikin samfurin, sunan yana da halaye da halayen da muke bi yayin haɓaka sabon sunan harhada magunguna."
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- Brand Institute announced its successful partnership with Global Blood Therapeutics (GBT) in naming their EMA-approved therapy, OXBRYTA, indicated for the treatment of hemolytic anemia due to sickle cell disease (SCD) in adult and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea).
- OXBRYTA is the first medicine approved in Europe that directly inhibits sickle hemoglobin (HbS) polymerization, the molecular basis of sickling and destruction of red blood cells in SCD.
- Since oxygenated sickle hemoglobin does not polymerize, OXBRYTA inhibits sickle hemoglobin polymerization and the resultant sickling and destruction of red blood cells.
